Proteomics

Dataset Information

0

Urine proteome in patients with metabolic associated fatty liver disease


ABSTRACT: Background Metabolic associated fatty liver disease (MAFLD) was recently proposed to replace non-alcoholic fatty liver disease (NAFLD), which is defined as ectopic fat deposition in the liver. Hepatic steatosis is an independent predictor for insulin resistance and cardiovascular risk and hence mortality. The aim of present study was to investigate the urine molecular pattern and potential urine biomarker to distinguish healthy control, mild and severe hepatic steatosis in MAFLD patients using proteomic data. Method Hepatic steatosis was measured by Magnetic resonance imaging (MRI) that measure the proton density fat fraction (MRI-PDFF). Proteomic measurements of urine samples were done by mass spectrometry. Linear regression analyses were used to detect significant associations between the biomarkers and clinical parameters. Western blot and Elisa were performed for validation. Results Multiple pathways have been compromised in MAFLD, including the carbohydrate derivative catabolic process, glycosaminoglycan process, aminoglycan metabolic process, inflammatory response, insulin-like growth factor receptor and GTPase complex. Alpha-1-acid glycoprotein 1 (ORM1) and ceruloplasmin were finally identified to be potential urine biomarkers to detect mild/severe hepatic steatosis.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Yong Zhang  

LAB HEAD: Yong Zhang

PROVIDER: PXD026333 | Pride | 2022-08-12

REPOSITORIES: Pride

altmetric image

Publications

Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease.

Liu Chang-Hai CH   Zheng Shanshan S   Wang Shisheng S   Wu Dongbo D   Jiang Wei W   Zeng Qingmin Q   Wei Yi Y   Zhang Yong Y   Tang Hong H  

Diagnostics (Basel, Switzerland) 20220607 6


Background: In patients with metabolic-associated fatty liver disease (MAFLD), hepatic steatosis is the first step of diagnosis, and it is a risk predictor that independently predicts insulin resistance, cardiovascular risk, and mortality. Urine biomarkers have the advantage of being less complex, with a lower dynamic range and fewer technical challenges, in comparison to blood biomarkers. Methods: Hepatic steatosis was measured by magnetic resonance imaging (MRI), which measured the proton dens  ...[more]

Similar Datasets

2022-02-17 | PXD027332 | Pride
2023-05-10 | PXD039894 | Pride
2020-05-26 | PXD013423 | Pride
2020-02-18 | GSE145404 | GEO
2011-04-02 | E-GEOD-8576 | biostudies-arrayexpress
2018-08-30 | PXD010209 | Pride
2021-06-17 | GSE178322 | GEO
2014-11-05 | E-GEOD-60349 | biostudies-arrayexpress
2009-04-07 | GSE14921 | GEO
2018-12-21 | GSE108609 | GEO